Getty Images
Merck & Co. Inc. MRK, -0.39% said Thursday the U.S. Food and Drug Administration has approved two new HIV-1 medicines, Delstrigo and Pifeltro.
The company said Delstrigo is a once-daily fixed-dose combination tablet of doravirine, lamivudine and tenofovir disoproxil fumarate, and Pifeltro is a new non-nucleoside reverse transcriptase inhibitor which is to be administered in combination with other antiretroviral medicines.
“As part of Merck’s 30-year commitment to the care of people with HIV, we are pleased to now bring forward these two new antiretroviral treatment options, Delstrigo and Pifeltro, which we believe offer a compelling clinical profile for clinicians and people living with HIV,” said Dr. George Hanna, vice president and therapeutic area head of infectious diseases, Global Clinical Development, Merck Research Laboratories.
A Merck spokesperson said Delstrigo treatments would cost $70 a day, while the price is $46 a day for Pifeltro.
An expanded version of this report appears on WSJ.com.
Also popular on WSJ.com:
How air in the Pacific Northwest became dirtier than Beijing’s.